东诚药业(002675.SZ)：177Lu-LNC1009注射液临床试验获批 目前国内外暂无同产品上市

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., received approval from the National Medical Products Administration of China for the clinical trial of Lu-LNC1009 injection, which will commence shortly [1] Group 1: Product Development - The product Lu-LNC1009 injection is a dual-target radioactive internal therapy drug that targets fibroblast activation protein (FAP) and integrin αvβ3 [1] - It is intended for the treatment of patients with advanced malignant solid tumors that are positive for FAP and integrin αvβ3 [1] - Currently, there are no similar products available in the domestic or international markets, and there are no related sales data [1]